The activation of ICOSL/ICOS signaling may trigger the Th2-type responses, and thus negatively regulates the immune cell responses against tumors, which is responsible for the poor survival in breast cancer patients (Wang et al., 2013). The gene discussed is ICOS; the disease is breast cancer.